Asset Details
Do you wish to reserve the book?
Efficacy and safety of drug-coated balloons in chronic total coronary occlusion recanalization: a systematic review and meta-analysis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Efficacy and safety of drug-coated balloons in chronic total coronary occlusion recanalization: a systematic review and meta-analysis
Do you wish to request the book?
Efficacy and safety of drug-coated balloons in chronic total coronary occlusion recanalization: a systematic review and meta-analysis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Efficacy and safety of drug-coated balloons in chronic total coronary occlusion recanalization: a systematic review and meta-analysis
2024
Overview
Background
With advancements in chronic total coronary occlusion (CTO) recanalization techniques and concepts, the success rate of recanalization has been steadily increasing. However, the current data are too limited to draw any reliable conclusions about the efficacy and safety of drug-coated balloons (DCBs) in CTO percutaneous coronary intervention (PCI). Herein, we conducted a meta-analysis to confirm the efficacy of DCB in CTO PCI.
Methods
We systematically searched PubMed, Web of Science and Embase from inception to July 25, 2023. The primary outcome was major advent cardiovascular events (MACE), including cardiac death, nonfatal myocardial infarction (MI), target lesion revascularization (TLR), and target vessel revascularization (TVR). The follow-up angiographic endpoints were late lumen enlargement (LLE), reocclusion and restenosis.
Results
Five studies with a total of 511 patients were included in the meta-analysis. Across studies, patients were predominantly male (72.9-85.7%) and over fifty years old. The summary estimate rate of MACE was 13.0% (95% CI 10.1%-15.9%, I
2
= 0%,
p
= 0.428). The summary estimate rates of cardiac death and MI were 2.2% (95% CI 0.7%-3.7%, I
2
= 0%,
p
= 0.873) and 1.2% (95% CI -0.2-2.6%, I
2
= 13.7%,
p
= 0.314), respectively. Finally, the pooled incidences of TLR and TVR were 10.1% (95% CI 5.7%-14.5%, I
2
= 51.7%,
p
= 0.082) and 7.1% (95% CI 3.0%-11.2%, I
2
= 57.6%,
p
= 0.070), respectively. Finally, the summary estimate rates of LLE, reocclusion and restenosis were 59.4% (95% CI 53.5–65.3%, I
2
= 0%,
p
= 0.742), 3.3% (95% CI 1.1–5.4%, I
2
= 0%,
p
= 0.865) and 17.5% (95% CI 12.9–22.0%, I
2
= 0%,
p
= 0.623), respectively.
Conclusion
Accordingly, DCB has the potential to be used as a treatment for CTO in suitable patients.
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
Subject
/ Angioplasty, Balloon, Coronary - adverse effects
/ Angioplasty, Balloon, Coronary - instrumentation
/ Angioplasty, Balloon, Coronary - mortality
/ Cardiovascular Agents - administration & dosage
/ Cardiovascular Agents - adverse effects
/ Coated Materials, Biocompatible
/ Complications and side effects
/ Coronary Occlusion - diagnostic imaging
/ Coronary Occlusion - mortality
/ Coronary Occlusion - therapy
/ Coronary Restenosis - diagnostic imaging
/ Coronary Restenosis - etiology
/ Coronary Restenosis - mortality
/ Female
/ Heart
/ Humans
/ Major advent cardiovascular event
/ Male
/ Medicine
/ Percutaneous coronary intervention
/ Stents
